Joshua E. Meyer, MD

Request an Appointment

Call 888-369-2427

Request Online

Clinical Locations

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Phone: 888-369-2427

Vice Chair, Translational Research, Department of Radiation Oncology

Professor, Department of Radiation Oncology

Director of Clinical and Translational Research, GI Service Line

Specialties

Gastrointestinal Radiation Oncology ;
Radiation Oncology

Areas of Expertise

Neuroendocrine Tumors, Colorectal Cancer, Liver, Gall Bladder & Bile Duct Cancer, Stomach (Gastric) Cancer, Esophageal Cancer, Pancreatic Cancer, Endobronchial Disease

Treatment Focus

Stereotactic Body Radiation Therapy (SBRT), Intensity Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Radioembolization, MR-guided Focused Ultrasound, Re-irradiation, Pulsed Low Dose Rate (PLDR) radiation, Brachytherapy, Anal Cancer

Research Program

Cancer Signaling and Microenvironment

Distinctions

Treatment Philosophy

As technologies and treatments continue to advance, there are more and more options in the details of how each cancer patient is treated. I work with my colleagues in other disciplines to define the most appropriate treatment for each individual patient. For each individual I am treating with radiation, I make a concerted effort to survey the landscape of potential treatment choices that I am able to bring to a particular patient’s care to ensure that the most effective, precise and targeted approach is being used in every situation. This allows patients to get the maximum amount of benefit from treatment with as small a risk of complications as possible.

Educational Background

Resident, Stich Radiation Center, Weill Cornell Medical Center, New York, NY
MD, University of Massachusetts Medical School, Worcester, MA, 2005
BA, Haverford College, Haverford, PA, 1998

Certifications

American Board of Radiology - Radiation Oncology

Memberships

American College of Radiology (ACR)
American Society of Clinical Oncology (ASCO)
American Society of Therapeutic Radiation Oncology (ASTRO)

Honors & Awards

Philadelphia Magazine Top Doctors, 2023-2024
ARRO Educator of the Year, 2015
Clinical Fellow, ASCO/AACR Workshop on Methods in Clinical Cancer Research, 2009
Roentgen Resident/Fellow Research Award, 2009
Lang Research Award, New York Hospital of Queens Residents and Fellows Day, 2009
American Radium Society Travel Grant, 2009
ASCO Cancer Foundation Merit Award, American Society of Clinical Oncology, 2009
International Society of Gastrointestinal Oncology Conference Educational Grant, 2008

Rob Brown

Colorectal Cancer
Lung Cancer

My cancer journey began in late 2021 when I began experiencing feelings of sickness, most often after eating. One night in February 2022, however, it became clear food was not the issue.

I’m the kind of guy who can sleep anytime, anywhere, so when the pain in my abdomen got so bad that I couldn’t sleep, I finally told my wife I needed to go to the ER. The doctors there did some testing and scans, but all they found was an infection, so they gave me an IV and antibiotics. After a few days, when I felt better, they sent me home.

VIEW PATIENT STORY

Janice Hudnell-Davis

Pancreatic Cancer

In January 2022, I listened to my body, and it may have saved my life. I initially went to the doctor because I had hemorrhoids that had been acting up for about a week. Not only was an over-the-counter medication not working, but I had also noticed a change in the color of my stool. Together, these were red flags that something wasn’t right.

VIEW PATIENT STORY

Steven Zatoris

Sarcoma
Colorectal Cancer
Lung Cancer

In 2021, I started having pain in my left leg. I visited my family doctor, and at first we thought it might be a deep vein thrombosis. When we ruled that out, I saw a vascular doctor in case it might be varicose veins. That doctor had me get an MRI, and after those results came back, I had to get a biopsy. That’s when the doctors confirmed that I had a stage IV tumor in my leg.

VIEW PATIENT STORY

Link to /sites/default/files/styles/patient_story/public/images/patient-stories/Demindo.JPG?h=d6e8a40f&itok=QBQLvzrT

Anthony Demidio

Colorectal Cancer

I’m 62 and I live in Bristol, Pa., with my wife Maryann. Between the two of us, we have four children and eight grandchildren (with another on the way). I also have a large extended family, and I work full time as a contractor. Needless to say, I’m a pretty busy guy!

VIEW PATIENT STORY

Research Interests

My interests are in clinical research for gastrointestinal cancers. This includes the new application of radiation technology to increase surgical resectability and cure rates. It also includes outcomes work to determine which management strategies are the most effective for these patients.

Selected Publications

Meyer J.E., Reddy S., ASO author reflections: Neoadjuvant chemoradiation impacts the prognostic effect of surgical margin status in pancreatic adenocarcinoma. Ann Surg Oncol. 29(1): 364-365, 2022. PMC9036528. https://www.ncbi.nlm.nih.gov/pubmed/34091775.

Paly J.J., Deng M., Lee C.T., Hayes S.B., Galloway T.J., Hallman M.A., Weiss S.E., Horwitz E.M., Price R.A., Ma C.C., Meyer J.E., Pelvic reirradiation utilizing pulsed low-dose rate radiation therapy. Am J Clin Oncol. 43(10): 748-751, 2020. https://www.ncbi.nlm.nih.gov/pubmed/32769406.

Wong J.K., Handorf E., Lee D., Jain R., Zhang E., Cooper H.S., Farma J.M., Dotan E., Meyer J.E., Toxicity and outcomes in older versus younger patients treated with trimodality therapy for locally advanced rectal cancer. J Geriatr Oncol. 11(8): 1331-1334, 2020. PMC7606716. https://www.ncbi.nlm.nih.gov/pubmed/32381438.

LS Wang, T Shaikh, EA Handorf, JP Hoffman, SJ Cohen, JE Meyer. Dose Escalation With a Vessel Boost in Borderline Resectable Pancreatic Adenocarcinoma Treated With Neoadjuvant Chemoradiation. Practical Radiation Oncology 90(1); 2015. PubMed

Shaikh T, Ruth K, Scoot WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE. “Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.” Ann Thorac Surg, 99(1):270-6, 2015 PubMed

Meyer JE, Panico VJ, Marconato HM, Sherr DL, Christos P, Pirog EC. “HIV positivity but not HPV/p16 status is associated with higher recurrence rate in anal cancer.” J Gastrointest Cancer, 44(4):450-5; 2013. PubMed

Meyer JE, Cohen SJ. “Beyond First-Line Therapy: Combining Chemotherapy and Radioembolization for Hepatic Colorectal Metastases.” J Nucl Med Radiat Ther 2:1-6; 2011

Meyer JE, Sherr DL. “Reply to receptive anal intercourse as a potential risk factor for rectal cancer.” Cancer. 117:3284-5; 2011.

Meyer JE, Narang T, Schnoll-Sussman FH, Pochapin MB, Christos PJ, Sherr DL. “Increasing incidence of rectal cancer in patients aged younger than 40 years.” Cancer. 116:4354-9; 2010. PubMed

Meyer JE, Sherr DL. “When Less Is More, When Less Is Less: Local Excision in Early Rectal Cancer.” Gastrointest Cancer Res. 3(3): 123-4; 2009. PubMed

... Expand